← Back to news
🔴 BreakingNewsFDAThursday, March 5, 2026 · March 5, 2026

FDA Grants Third Approval Under the National Priority Voucher Program

WHY IT MATTERS

FDA announcement relevant to rare disease patients and caregivers.

The U.S. Food and Drug Administration today approved teclistamab in combination with daratumumab hyaluronidase-fihj, Tec-Dara, to treat adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.

View FDA Announcement
Read the original at FDA
FDA ApprovalTreatment

Related news

FDA
FDA Approves XTORO
XTORO (FINAFLOXACIN) received FDA approval.
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.
FDA
FDA Approves SABRIL
SABRIL (VIGABATRIN) received FDA approval.
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.